No quarterly revenue total was found in Cogent Biosciences, Inc.'s SEC filings.
Cogent Biosciences, Inc. (COGT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$77.6 million. As of Jun 30, 2026 it held $792.3 million in cash and investments and $244.3 million in total debt.
Revenue
—
Net income
$-96.41M
-31.1% vs year-ago quarter
Operating cash flow
$-77.27M
-41.7% vs year-ago quarter
Free cash flow
$-77.64M
-42.0% vs year-ago quarter
EPS
$-0.52
+1.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
173.52M
+24.2% vs year-ago quarter
Net cash
$548.04M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COGT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1622229
- Former names
- Unum Therapeutics Inc. (until Oct 5, 2020); Unum Therapeutics, Inc. (until Mar 30, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$102.6M | -$103.6M | -$99.5M | -$83.4M | -$75.6M |
| Net income | -$96.4M | -$97.4M | -$102.5M | -$80.9M | -$73.5M |
| Diluted EPS | -$0.52 | -$0.53 | -$0.68 | -$0.50 | -$0.53 |
| Operating cash flow | -$77.3M | -$86.9M | -$79.1M | -$64.3M | -$54.5M |
| Free cash flow | -$77.6M | -$87.3M | -$79.9M | -$64.4M | -$54.7M |
| Total assets | $834.5M | $903.0M | $937.6M | $425.9M | $274.8M |
| Total liabilities | $302.2M | $295.3M | $301.2M | $123.5M | $119.8M |
| Stockholders' equity | $532.4M | $607.7M | $636.4M | $302.5M | $155.0M |
| Cash and investments | $792.3M | $866.4M | $900.8M | $390.9M | $237.8M |
| Total debt | $244.3M | $238.7M | $238.8M | $60.6M | $60.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 2, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
All 614 Cogent Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.